IL161378A0 - Treatment of acute myeloid leukemia with indolinone compounds - Google Patents
Treatment of acute myeloid leukemia with indolinone compoundsInfo
- Publication number
- IL161378A0 IL161378A0 IL16137802A IL16137802A IL161378A0 IL 161378 A0 IL161378 A0 IL 161378A0 IL 16137802 A IL16137802 A IL 16137802A IL 16137802 A IL16137802 A IL 16137802A IL 161378 A0 IL161378 A0 IL 161378A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- myeloid leukemia
- acute myeloid
- indolinone compounds
- indolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33062301P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034525 WO2003035009A2 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161378A0 true IL161378A0 (en) | 2004-09-27 |
Family
ID=23290562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16137802A IL161378A0 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20030130280A1 (es) |
| EP (1) | EP1446117A4 (es) |
| JP (1) | JP2005511540A (es) |
| KR (1) | KR20040062591A (es) |
| CN (1) | CN101052394A (es) |
| AU (1) | AU2002360314B2 (es) |
| BR (1) | BR0213960A (es) |
| CA (1) | CA2464790A1 (es) |
| CZ (1) | CZ2004619A3 (es) |
| HU (1) | HUP0500422A3 (es) |
| IL (1) | IL161378A0 (es) |
| IS (1) | IS7222A (es) |
| MX (1) | MXPA04003853A (es) |
| NZ (1) | NZ532405A (es) |
| PL (1) | PL370553A1 (es) |
| TN (1) | TNSN04065A1 (es) |
| TW (1) | TWI259081B (es) |
| WO (1) | WO2003035009A2 (es) |
| ZA (1) | ZA200403091B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04006992A (es) | 2002-02-15 | 2004-11-10 | Upjohn Co | Procedimiento para preparar derivados de indolinona. |
| US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| TW200418836A (en) * | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
| US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| CA2540639C (en) * | 2003-10-02 | 2010-08-31 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| MX2007014087A (es) * | 2005-05-12 | 2008-02-07 | Pfizer | Combinaciones y procedimientos para usar un compuesto de indolinona. |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| WO2007034327A1 (en) * | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| US20090305382A1 (en) * | 2005-09-22 | 2009-12-10 | The Scripps Research Institute | Alkoxy indolinone based protein kinase inhibitors |
| BRPI0617489A2 (pt) * | 2005-10-18 | 2011-07-26 | Janssen Pharmaceutica Nv | compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase |
| DK1973910T3 (da) * | 2006-01-27 | 2013-08-12 | Shanghai Hengrui Pharm Co Ltd | Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer |
| WO2007124322A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| DK2021335T3 (da) | 2006-04-20 | 2011-09-05 | Janssen Pharmaceutica Nv | Heterocykliske forbindelser som C-FMS-kinasehæmmere |
| ES2383084T3 (es) | 2006-12-04 | 2012-06-18 | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. | Derivados de 3-pirrolo[b]ciclohexilen-2-dihidroindolinona y usos de los mismos |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| CA2713112A1 (en) * | 2008-02-13 | 2009-08-20 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
| EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2098521A1 (en) | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
| US8501962B2 (en) | 2008-06-23 | 2013-08-06 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
| EP2138167A1 (en) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
| SG182480A1 (en) | 2010-01-12 | 2012-08-30 | Ab Science | Thiazole and oxazole kinase inhibitors |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| JP6009457B2 (ja) * | 2010-12-23 | 2016-10-19 | ネクター セラピューティクス | ポリマー−デスエチルスニチニブコンジュゲート |
| JP6002149B2 (ja) | 2010-12-23 | 2016-10-05 | ネクター セラピューティクス | ポリマー−スニチニブコンジュゲート |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| TWI569799B (zh) | 2012-09-21 | 2017-02-11 | 安羅格製藥股份有限公司 | 抑制組成型活性磷酸化ｆｌｔ３激酶的方法 |
| KR102173874B1 (ko) | 2012-12-21 | 2020-11-05 | 에피자임, 인코포레이티드 | 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도 |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| CN103274986A (zh) * | 2013-06-20 | 2013-09-04 | 湖南欧亚生物有限公司 | 一种舒尼替尼中间体的合成和精制方法 |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| JP2017523972A (ja) | 2014-07-31 | 2017-08-24 | アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） | Ｆｌｔ３レセプターアンタゴニスト |
| CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| EP3359155A4 (en) | 2016-11-02 | 2019-05-22 | Arog Pharmaceuticals, Inc. | CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES |
| AU2018269678A1 (en) | 2017-05-17 | 2019-12-12 | Biodol Therapeutics | FLT3 inhibitors for improving pain treatments by opioids |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| US11713310B2 (en) | 2020-07-20 | 2023-08-01 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999061422A1 (en) * | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| ATE331514T1 (de) * | 1999-12-22 | 2006-07-15 | Sugen Inc | Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase |
| SI1255752T1 (sl) * | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| EP1349852A2 (en) * | 2000-12-20 | 2003-10-08 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| BR0213185A (pt) * | 2001-10-10 | 2004-09-14 | Sugen Inc | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase |
-
2002
- 2002-10-25 TW TW091125049A patent/TWI259081B/zh not_active IP Right Cessation
- 2002-10-28 EP EP02795563A patent/EP1446117A4/en not_active Withdrawn
- 2002-10-28 WO PCT/US2002/034525 patent/WO2003035009A2/en active IP Right Grant
- 2002-10-28 CN CNA028229592A patent/CN101052394A/zh active Pending
- 2002-10-28 BR BR0213960-0A patent/BR0213960A/pt not_active IP Right Cessation
- 2002-10-28 JP JP2003537578A patent/JP2005511540A/ja not_active Withdrawn
- 2002-10-28 CZ CZ2004619A patent/CZ2004619A3/cs unknown
- 2002-10-28 IL IL16137802A patent/IL161378A0/xx unknown
- 2002-10-28 AU AU2002360314A patent/AU2002360314B2/en not_active Ceased
- 2002-10-28 CA CA002464790A patent/CA2464790A1/en not_active Abandoned
- 2002-10-28 PL PL02370553A patent/PL370553A1/xx not_active Application Discontinuation
- 2002-10-28 NZ NZ532405A patent/NZ532405A/en unknown
- 2002-10-28 HU HU0500422A patent/HUP0500422A3/hu unknown
- 2002-10-28 KR KR10-2004-7006222A patent/KR20040062591A/ko not_active Application Discontinuation
- 2002-10-28 US US10/281,266 patent/US20030130280A1/en not_active Abandoned
- 2002-10-28 MX MXPA04003853A patent/MXPA04003853A/es not_active Application Discontinuation
-
2004
- 2004-04-15 IS IS7222A patent/IS7222A/is unknown
- 2004-04-16 TN TNP2004000065A patent/TNSN04065A1/en unknown
- 2004-04-22 ZA ZA200403091A patent/ZA200403091B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500422A2 (hu) | 2005-11-28 |
| EP1446117A4 (en) | 2008-01-23 |
| CZ2004619A3 (cs) | 2005-03-16 |
| CN101052394A (zh) | 2007-10-10 |
| BR0213960A (pt) | 2004-08-31 |
| HUP0500422A3 (en) | 2009-09-28 |
| IS7222A (is) | 2004-04-15 |
| TNSN04065A1 (en) | 2006-06-01 |
| WO2003035009A2 (en) | 2003-05-01 |
| WO2003035009A3 (en) | 2004-03-18 |
| CA2464790A1 (en) | 2003-05-01 |
| PL370553A1 (en) | 2005-05-30 |
| JP2005511540A (ja) | 2005-04-28 |
| NZ532405A (en) | 2005-12-23 |
| ZA200403091B (en) | 2005-01-14 |
| US20030130280A1 (en) | 2003-07-10 |
| TWI259081B (en) | 2006-08-01 |
| EP1446117A2 (en) | 2004-08-18 |
| MXPA04003853A (es) | 2005-02-17 |
| KR20040062591A (ko) | 2004-07-07 |
| AU2002360314B2 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161378A0 (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
| ZA200305691B (en) | The use of substituted azetidione compounds for the treatment of sitosterolemia | |
| SI1578446T1 (sl) | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega | |
| IL157425A0 (en) | Treatment of solid tumours with paramycin derivatives | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| IL161511A0 (en) | Therapeutic isoquinoline compounds | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| IL161509A0 (en) | Therapeutic quinolone compounds with 5-ht-antogonistic properties | |
| IL161597A0 (en) | Therapeutic quinoline compounds with 5-ht-antagonistic properties | |
| PL377464A1 (pl) | Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN | |
| PL378762A1 (pl) | Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| HU0103986D0 (en) | New compounds with therapeutic effect | |
| HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| AU2002364711A8 (en) | Substituted 5-hydroxy-indole compounds for the treatment of glaucoma | |
| GB0103031D0 (en) | Novel treatment | |
| AU2003301905A8 (en) | Compositions and methods for treating acute myeloid leukemia | |
| SI1485352T1 (en) | Azaspiro compounds for the treatment of pain | |
| EP1453529A4 (en) | TREATMENT OF SEPSIS WITH TAFI | |
| AU2002341485A1 (en) | Treatment of polyaluminium compounds | |
| SI1485057T1 (sl) | Derivati azaspiro spojin za zdravljenje bolecine | |
| GB0120654D0 (en) | Treatment of anemia | |
| GB0120406D0 (en) | Treatment of anemia | |
| GB0101636D0 (en) | Therapeutic compounds | |
| GB0100599D0 (en) | Therapeutic compounds |